{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:10:14Z","timestamp":1786119014152,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/md.0b013e318190f170","type":"journal-article","created":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T03:09:55Z","timestamp":1226372995000},"page":"345-364","source":"Crossref","is-referenced-by-count":129,"title":["A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases"],"prefix":"10.1097","volume":"87","author":[{"given":"Manuel","family":"Ramos-Casals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Brito-Zer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210226","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Behcet's disease.","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"R2-6-20210226","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-6-20210226","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"R4-6-20210226","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of rituximab in the treatment of patients with dermatomyositis.","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"key":"R5-6-20210226","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2005.048744","article-title":"Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.","volume":"65","author":"Efthimiou","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R6-6-20210226","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-6-20210226","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force.","volume":"129","author":"Guyatt","year":"2006","journal-title":"Chest"},{"key":"R8-6-20210226","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"R9-6-20210226","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/art.10231","article-title":"Etanercept in the treatment of adult patients with Still's disease.","volume":"46","author":"Husni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R10-6-20210226","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Societe Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pediatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still's disease. Preliminary experience in France.","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R11-6-20210226","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study.","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R12-6-20210226","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS).","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R13-6-20210226","first-page":"98","article-title":"Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study.","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"R14-6-20210226","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R15-6-20210226","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis.","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"R16-6-20210226","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"R17-6-20210226","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"R18-6-20210226","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R19-6-20210226","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease.","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R20-6-20210226","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1191\/0961203306lu2278rr","article-title":"The world of biologics.","volume":"15","author":"Symmons","year":"2006","journal-title":"Lupus"},{"key":"R21-6-20210226","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial.","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R22-6-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"R23-6-20210226","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study.","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e318190f170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:12:52Z","timestamp":1786036372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-200811000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e318190f170","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}